UniQure (QURE) got here out with a quarterly lack of $1.02 per share versus the Zacks Consensus Estimate of a lack of $1.11. This compares to lack of $0.79 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of 8.11%. 1 / 4 in the past, it was anticipated that this human gene remedy firm would submit a lack of $0.96 per share when it truly produced a lack of $0.84, delivering a shock of 12.50%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates thrice.
uniQure
The sustainability of the inventory’s instant worth motion primarily based on the recently-released numbers and future earnings expectations will largely rely upon administration’s commentary on the earnings name.
UniQure shares have misplaced about 9.2% because the starting of the 12 months versus the S&P 500’s decline of -19.1%.
What’s Subsequent for uniQure?
Whereas uniQure has outperformed the market to date this 12 months, the query that involves traders’ minds is: what’s subsequent for the inventory?
There aren’t any straightforward solutions to this key query, however one dependable measure that may assist traders tackle that is the corporate’s earnings outlook. Not solely does this embrace present consensus earnings expectations for the approaching quarter(s), but in addition how these expectations have modified these days.
Empirical analysis reveals a robust correlation between near-term inventory actions and developments in earnings estimate revisions. Buyers can observe such revisions by themselves or depend on a tried-and-tested score instrument just like the Zacks Rank, which has a formidable observe file of harnessing the facility of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for uniQure: combined. Whereas the magnitude and path of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out in step with the market within the close to future. You’ll be able to see the entire listing of at this time’s Zacks #1 Rank (Robust Purchase) shares right here.
It will likely be attention-grabbing to see how estimates for the approaching quarters and present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.45 on $54 million in revenues for the approaching quarter and -$3.61 on $41.39 million in revenues for the present fiscal 12 months.
Buyers ought to be aware of the truth that the outlook for the business can have a cloth affect on the efficiency of the inventory as properly. When it comes to the Zacks Trade Rank, Medical – Biomedical and Genetics is at the moment within the prime 20% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
One other inventory from the identical business, Regeneron (REGN), has but to report outcomes for the quarter ended September 2022. The outcomes are anticipated to be launched on November 3.
This biopharmaceutical firm is predicted to submit quarterly earnings of $9.65 per share in its upcoming report, which represents a year-over-year change of -37.2%. The consensus EPS estimate for the quarter has been revised 4% larger over the past 30 days to the present stage.
Regeneron’s revenues are anticipated to be $2.79 billion, down 19.1% from the year-ago quarter.
Zacks Names “Single Finest Choose to Double”
From 1000’s of shares, 5 Zacks consultants every have chosen their favourite to skyrocket +100% or extra in months to return. From these 5, Director of Analysis Sheraz Mian hand-picks one to have probably the most explosive upside of all.
It’s a little-known chemical firm that’s up 65% over final 12 months, but nonetheless filth low cost. With unrelenting demand, hovering 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail traders might leap in at any time.
This firm might rival or surpass different current Zacks’ Shares Set to Double like Boston Beer Firm which shot up +143.0% in little greater than 9 months and NVIDIA which boomed +175.9% in a single 12 months.
Free: See Our Prime Inventory and 4 Runners Up >>
Need the most recent suggestions from Zacks Funding Analysis? Immediately, you may obtain 7 Finest Shares for the Subsequent 30 Days. Click on to get this free report
uniQure N.V. (QURE): Free Inventory Evaluation Report
Regeneron Prescribed drugs, Inc. (REGN): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
